Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Atrial fibrillation is a frequent complication among patients with severe coronavirus disease-2019 (COVID-19) infection. Both direct and indirect mechanisms through COVID-19 have been described to explain this relationship. COVID-19 infection increases the risk of developing both arterial and venous...

Full description

Bibliographic Details
Main Authors: Teodoro Iturbe-Hernandez, Luis García de Guadiana Romualdo, Ignacio Gil Ortega, Antonio Martínez Francés, Olga Meca Birlanga, Juan José Cerezo-Manchado
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-09-01
Series:Drugs in Context
Subjects:
atrial fibrillation
covid-19
dabigatran
direct oral anticoagulants
hepatotoxicity
Online Access:https://www.drugsincontext.com/dabigatran-the-oral-anticoagulant-of-choice-at-discharge-in-patients-with-non-valvular-atrial-fibrillation-and-covid-19-infection-the-anibal-protocol

Internet

https://www.drugsincontext.com/dabigatran-the-oral-anticoagulant-of-choice-at-discharge-in-patients-with-non-valvular-atrial-fibrillation-and-covid-19-infection-the-anibal-protocol

Similar Items